VYNE Therapeutics Inc.

VYNE | NASDAQ

Price Alert Chart Builder DCF Calculator

$28.56

$0.00 (0.00%)

Nov 2, 2026, 10:12 AM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+0.00%

(1D)

No price chart data available for 1D timeframe.

Rating

Updated: Sep 30, 2026

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $19.07M

1D Range

23.37 28.72

52W Range

14.03 74.47

Valuation (TTM)

PE -0.04

PB 686.82

EV/EBITDA -0.42

Valuation (NTM)

Forward PE N/A

Forward PEG -0.00

Price Target $5.75

Cash Flow

FCF Yield -88.8%

SBC Adj. FCF Yield -98.9%

SBC Impact -11.4%

Margins

Gross Margin 99.4%

Operating Margin -4877.1%

FCF Margin -1773.1%

Growth (CAGR)

Revenue 3Y | 5Y 32.9% | -34.8%

Dil EPS 3Y | 5Y -94.0% | 11.2%

FCF 3Y | 5Y 17.6% | 13.6%

Returns

ROA -139870.7%

ROE -199.7%

ROIC -159961.5%

Financial Health

Net Cash

$29.01K

Current Ratio 12.53

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical...

Sector Healthcare

Industry Biotechnology

Employees 10

IPO Date Jan 25, 2018

Website vynetherapeutics.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.